Traders Buy High Volume of Put Options on Merck & Co (MRK)
Merck & Co (NYSE:MRK) was the recipient of some unusual options trading on Friday. Stock traders bought 17,568 put options on the company, Analyst RN reports. This is an increase of approximately 214% compared to the average volume of 5,600 put options.
Several analysts have recently commented on the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Friday, October 18th. Separately, analysts at BMO Capital Markets cut their price target on shares of Merck & Co to $48.00 in a research note to investors on Thursday, October 17th. They now have a “market perform” rating on the stock. Finally, analysts at Sanford C. Bernstein downgraded shares of Merck & Co from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, October 14th. They now have a $50.00 price target on the stock, down previously from $53.00. Two analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. Merck & Co currently has a consensus rating of “Hold” and a consensus target price of $50.96.
Merck & Co (NYSE:MRK) traded up 0.69% on Friday, hitting $46.54. 17,878,728 shares of the company’s stock traded hands. Merck & Co has a one year low of $40.02 and a one year high of $50.16. The stock’s 50-day moving average is $47.92 and its 200-day moving average is $46.68. The company has a market cap of $136.2 billion and a P/E ratio of 27.68.
Merck & Co (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the previous year, the company posted $1.05 earnings per share. The company’s revenue for the quarter was down 10.6% on a year-over-year basis.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.